ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors

Partnership combines ARTBIO’s AlphaDirect™ platform for 212Pb-based alpha radioligand therapies with 3B Pharmaceuticals’ expertise in peptide radioligand therapy discovery and development ARTBIO gains exclusive global license for highly novel program close to clinical development…